Skip to content

Effect of a 4-week Post-exercise Sauna Bathing on Targeted Gut Microbiota

Effect of a 4-week Post-exercise Sauna Bathing on Targeted Gut Microbiota and Intestinal Barrier Function in Healthy Men: a Randomized Controlled Pilot Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05277597
Enrollment
15
Registered
2022-03-14
Start date
2020-02-10
Completion date
2021-06-25
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Males

Keywords

gut microbiota, exercise, sauna bathing, intestinal barrier

Brief summary

Body temperature fluctuations induced by acute exercise bouts may influence the intestinal barrier with related effects on epithelial permeability, immune responses, and release of metabolites produced by the gut microbiota.

Detailed description

Untrained males aged 22±1.5 years were randomly assigned to exercise training (ET) with or without post-exercise sauna treatments (S). Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment. The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program. Blood samples were analysed for the concentration of high-sensitivity C-reactive protein (hsCRP) and complete blood counts. Stool samples were analysed for pH, quantitative and qualitative measures of targeted bacteria and fungi, zonulin, and secretory immunoglobulin A. This study evaluated the effects of post-exercise sauna bathing in young men undergoing endurance training on gut bacteria inflammation and intestinal barrier function. Investigators hypothesized that sauna bathing applied immediately after a physical training session may impact homeostatic control of the gut microbiota and the function of the intestinal barrier.

Interventions

DIAGNOSTIC_TESTThe exercise 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.

Participants in the group ET+S (n=8) exercised 60 minutes, 3 times per week, on a bicycle ergometer followed by a 30-minute dry Finish sauna treatment.Blood and stool samples were collected before and after the 4-week training program.

DIAGNOSTIC_TESTThe same exercise training program without the sauna treatments

The control group (ET, n=7) engaged in the same exercise training program without the sauna treatments. Blood and stool samples were collected before and after the 4-week training program.

Sponsors

David C. Nieman
CollaboratorUNKNOWN
Tomasz Cisoń
CollaboratorUNKNOWN
Joanna Szurkowska
CollaboratorUNKNOWN
Mirosława Gałęcka
CollaboratorUNKNOWN
Dariusz Sitkowski
CollaboratorUNKNOWN
Zbigniew Szyguła
CollaboratorUNKNOWN
Poznan University of Physical Education
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

This study used a randomized, parallel group design. The participants were randomly assigned to exercise training (ET) without or with post-exercise sauna treatments (ET+S) by using a permuted blocks of block size 4. design with a computer.

Eligibility

Sex/Gender
MALE
Age
18 Years to 25 Years
Healthy volunteers
Yes

Inclusion criteria

* absence of medical contraindications such as epilepsy,addiction to medicines, alcohol and drugs, cancer, blood clotting disorders, * no infections in the last 4 weeks prior to the study, * no injuries in the last 4 weeks prior to the study.

Exclusion criteria

* the intake of antibiotics, steroids, oral antifungal agents (except for topical antifungals), antiparasitic agents, pre- and/or probiotics, * history of travel to tropical countries during the last 4 weeks before the study, * history of adverse responses to sauna bathing.

Design outcomes

Primary

MeasureTime frameDescription
Change from abundance of Faecalibacterium prausnitzi of the genus Faecalibacterium, Akkermansia muciniphila of the genus Akkermansia, Bifidobacterium spp. of the genus Actinobacteria and Bacteroides spp. of the genus Bacteroidetes at 4 weeks.baseline and immediately after the interventionBacterial DNA was isolated from stool samples using the QIAamp Fast DNA Stool Mini Kit (QIAGEN, Danish). The anaerobic bacteria were determined by Real-Time PCR with appropriate primers (ThermoFisher Scientific, USA).The results of quantitative bacterial analysis were converted to the decimal logarithm (Log10). The entire Real-Time PCR methodology was developed and validated by the Institute of Microecology in Herborn, Germany
Change from the concentrations of sIgA (marker of mucosal immunity), and zonulin (marker of intestinal permeability) in stool at 4 weeks.baseline and immediately after the interventionSecretory immunoglobulin A concentrations in stool samples were determined with the Secretory IgA test (ImmuChrom GmbH, Heppenheim, Germany). Zonulin concentrations were assessed using the IKD Zonulin ELISA Kit (Immunodiagnostik AG, Bensheim, Germany).
Change from the concentration of high-sensitivity C-reactive protein (hsCRP) at 4 weeks.baseline and immediately after the interventionThe concentration of hsCRP was measured by immunoenzymatic assay using a commercially available kit (DRG International Inc., Springfield Township, NJ, USA).

Secondary

MeasureTime frameDescription
Change from the white blood cell counts (WBC) and subsets at 4 weeks.baseline and immediately after the interventionBlood samples (approx. 2 ml) were taken from the antecubital vein.Complete blood count indices were determined by flow cytometry with a Synergy 2 SIAFRT analyser (Bio Tek, Winooski, VT, USA).
Change feom cardio-respiratory measures at 4 weeks.baseline and immediately after the interventionPeak oxygen uptake (VO2peak) was assessed with MetaMax 3B analyzer (Cortex, Germany) using a graded exercise test (GXT) with a cycloergometer Cyclus2 (Avantronic, Germany).

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026